ClinicalTrials.gg
CompletedNCT02000622OlympiADUpdated Feb 13, 2026Results posted

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

A Phase 3 interventional study of Olaparib and Physician's choice chemotherapy in Breast Cancer Metastatic, BRCA 1 Gene Mutation and BRCA 2 Gene Mutation, sponsored by AstraZeneca. Completed at 171 sites in 19 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing olaparib in Breast Neoplasms — 11 open to participants now, 25 under way, 4 of them phase 3. olaparib · Breast Neoplasms.

Enrollment
5th of 51
302 · median 54
Started
2014
with 2 others
Phase 3
5 of 51
none open now
Registered
9th of 51
by date
Lead sponsor
11 of 51
AstraZeneca

Among the 51 studies testing olaparib in Breast Neoplasms, this one is the 5th largest by enrollment, is one of 3 that started in 2014, is one of 5 in phase 3, and was the 9th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 51 studies testing olaparib in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing olaparib in Breast Neoplasms, or all of them as a file.
02

Study summary

This open label, randomised, controlled, multi-centre phase III study will assess the efficacy and safety of single agent olaparib vs standard of care based on physician's choice of capecitabine, vinorelbine or eribulin in metastatic breast cancer patients with gBRCA 1/2 mutations.

03

Conditions studied

  • Breast Cancer Metastatic
  • BRCA 1 Gene Mutation
  • BRCA 2 Gene Mutation

Keywords

  • Breast Cancer
  • Metastatic
  • Olaparib
  • BRCA
  • PARP inhibitor
  • HER2
  • chemotherapy
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Germline mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious.
  • or cytologically confirmed breast cancer with evidence of disease.
  • Prior therapy with an anthracycline and a taxane in either an or metastatic setting.
  • Prior platinum allowed as long as no breast cancer progression occurred on treatment or if given in adjuvant/neoadjuvant setting at least 12 months from last dose to study entry elapsed.
  • ER/PR breast cancer positive patients must have received and progressed on at least one endocrine therapy (adjuvant or metastatic), or have disease that the treating physician believes to be inappropriate for endocrine therapy.
  • performance status 0-1.
  • Adequate bone marrow, kidney and liver function.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with PARP inhibitor.
  • Patients with positive disease.
  • More than 2 for breast cancer.
  • Untreated and/or uncontrolled .
  • Prior unless curatively treated and disease-free for > 5 years prior to study entry. Prior adequately treated non-melanoma skin cancer, in situ cancer of the cervix, DCIS or stage I grade 1 endometrial cancer allowed.
  • Known (Human Immunodeficiency Virus) infection.
  • Pregnant or breast-feeding women.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
302 participants (actual)

Study arms

  • Experimental
    Olaparib

    Olaparib tablet 300mg bd po

    Drug: Olaparib

  • Active comparator
    Physician's choice chemotherapy

    Capecitabine 2500 mg/m2 d1-14 q 21, or Vinorelbine 30 mg/m2 d1,8 q 21, or Eribulin 1.4 mg/m2 d1,8 q 21

    Drug: Physician's choice chemotherapy

Interventions

  • Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.

  • DrugPhysician's choice chemotherapy

    Investigators will declare one of the following regimens: * Capecitabine 2500 mg/m2 po daily (divided in 2 doses) x 14 days, repeat every 21 days * Vinorelbine 30 mg/m2 IV Day 1 and Day 8, repeat every 21 days * Eribulin 1.4 mg/m2 IV Day 1 and Day 8, repeat every 21 days

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1)

    Time from randomisation to the earliest of objective radiological progression or death by any cause in the absence of objective progression. Objective radiological progression is defined using Response Evaluation Criteria In Solid Tumours (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.

Secondary outcomes

  1. Time to Second Progression or Death (PFS2)

    Time from randomisation to the earliest of the progression event subsequent to the first objective radiological progression, or death. Second progression may involve any of; objective radiological or symptomatic progression or death. Objective radiological progression is defined using Response Evaluation Criteria In Solid Tumours (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Symptomatic progression is assessed by investigators based on clinical examination.

    Time frame: Second progression status reviewed every 8 weeks following the first objective radiological progression as per investigator assessment. Assessed up to a maximum of 30 months.

  2. Overall Survival (OS)

    Time from randomisation until death due to any cause.

    Time frame: Survival status reviewed every 3 weeks until treatment discontinued, then every 8 weeks. Assessed up to a maximum of 30 months.

  3. Objective Response Rate (ORR) Using Blinded Independent Central Review (BICR) Data Assessed by Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1)

    Number of responders according to blinded independent central review (BICR) assessment. Per Response Evaluation Criteria In Solid Tumours Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR) is defined as the disappearance of all target lesions; Partial Response (PR) is defined as \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response = CR + PR.

    Time frame: Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.

  4. Adjusted Mean Change in Global Health Status/Quality of Life (QoL) Score From the European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire (EORTC QLQ-C30)

    Change from baseline in global health status/quality of life (QoL) score assessed using a mixed model for repeated measures (MMRM) analysis, including all post-baseline global health status/QoL scores up to the latest scheduled visit where at least 20 patients on each treatment arm have a score. Global health status/QoL score is on a scale from 0 to 100. A higher score represents an improved health status/QoL.

    Time frame: EORTC QLQ-C30 assessments performed at baseline then every ~6 weeks until objective radiological disease progression. Assessed up to a maximum of 30 months.

  5. Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) in Patients Confirmed as Myriad CDx gBRCAm

    Time from randomisation to the earliest of objective radiological progression or death by any cause in the absence of objective progression. Objective radiological progression is defined using Response Evaluation Criteria In Solid Tumours Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Assessed in patients with a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (gene sequencing and large rearrangement analysis).

    Time frame: Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.

  6. Overall Survival (OS) at Final OS

    Time from randomisation until death due to any cause.

    Time frame: Survival status reviewed every 3 weeks until treatment discontinued, then every 8 weeks. Assessed up to a maximum of 40 months.

  7. Overall Survival (OS) at Extended OS

    Time from randomisation until death due to any cause.

    Time frame: Survival status reviewed every 3 weeks until treatment discontinued, then every 8 weeks until Sep 2017 (final OS DCO), then every 3 months. Assessed up to a maximum of 64 months.

Other outcomes

  1. Time to First Subsequent Cancer Therapy or Death (TFST)

    Time from randomisation to the earliest of first subsequent cancer therapy start date following study treatment discontinuation, or death.

    Time frame: Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation. Assessed up to a maximum of 30 months.

  2. Time to Second Subsequent Cancer Therapy or Death (TSST)

    Time from randomisation to the earliest of second subsequent cancer therapy start date following study treatment discontinuation, or death.

    Time frame: Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation. Assessed up to a maximum of 30 months.

  3. Time to First Subsequent Cancer Therapy or Death (TFST) at Extended OS

    Time from randomisation to the earliest of first subsequent cancer therapy start date following study treatment discontinuation, or death.

    Time frame: Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation until Sep 2017 (final OS DCO), then every 3 months. Assessed up to a maximum of 64 months.

  4. Time to Second Subsequent Cancer Therapy or Death (TSST) at Extended OS

    Time from randomisation to the earliest of second subsequent cancer therapy start date following study treatment discontinuation, or death.

    Time frame: Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation until Sep 2017 (final OS DCO), then every 3 months. Assessed up to a maximum of 64 months.

07

Results

Posted Dec 22, 2017

Participant flow

The first patient was enrolled on 27 March 2014 and the last patient on 30 October 2015. Patients were randomized at 125 centres across 19 countries in North America, South America, Europe and Asia.

Participant flow — Overall Study
MilestoneOlaparib 300 mg bdChemotherapy
Started20597
Completed3617
Not completed16980
Withdrew: Withdrawal by subject57
Withdrew: Lost to follow-up40
Withdrew: Death15973
Withdrew: Withdrawn due to site closure10

Outcome measures

PrimaryProgression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1)

Time from randomisation to the earliest of objective radiological progression or death by any cause in the absence of objective progression. Objective radiological progression is defined using Response Evaluation Criteria In Solid Tumours (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.
Reported as:
Median · Months
Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1)
MonthsOlaparib 300 mg bdChemotherapy
Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1)7.0 (5.7 to 8.3)4.2 (2.8 to 4.3)
Statistical analysis
  • Olaparib 300 mg bd vs Chemotherapy · Log Rank · p = 0.0009 (A priori threshold for statistical significance (2-sided) is 0.05.) · Hazard ratio (hr): 0.58 · 95% CI 0.43 to 0.80Hazard ratio \<1 favours olaparib.
SecondaryTime to Second Progression or Death (PFS2)

Time from randomisation to the earliest of the progression event subsequent to the first objective radiological progression, or death. Second progression may involve any of; objective radiological or symptomatic progression or death. Objective radiological progression is defined using Response Evaluation Criteria In Solid Tumours (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Symptomatic progression is assessed by investigators based on clinical examination.

Time frame:
Second progression status reviewed every 8 weeks following the first objective radiological progression as per investigator assessment. Assessed up to a maximum of 30 months.
Reported as:
Median · Months
Time to Second Progression or Death (PFS2)
MonthsOlaparib 300 mg bdChemotherapy
Time to Second Progression or Death (PFS2)13.2 (10.9 to 15.3)9.3 (7.3 to 10.4)
Statistical analysis
  • Olaparib 300 mg bd vs Chemotherapy · Log Rank · p = 0.0033 (PFS2 tested using a multiple testing procedure with a recycling strategy. With 157 PFS2 events, a priori threshold for statistical significance (2-sided) was 0.008.) · Hazard ratio (hr): 0.57 · 95% CI 0.40 to 0.83Hazard ratio \<1 favours olaparib.
SecondaryOverall Survival (OS)

Time from randomisation until death due to any cause.

Time frame:
Survival status reviewed every 3 weeks until treatment discontinued, then every 8 weeks. Assessed up to a maximum of 30 months.
Reported as:
Median · Months
Overall Survival (OS)
MonthsOlaparib 300 mg bdChemotherapy
Overall Survival (OS)19.3 (16.7 to 21.8)19.6 (14.1 to 24.2)
Statistical analysis
  • Olaparib 300 mg bd vs Chemotherapy · Log Rank · p = 0.5665 (OS tested using a multiple testing procedure with a recycling strategy. With 140 OS events, a priori threshold for statistical significance (2-sided) was 0.018.) · Hazard ratio (hr): 0.90 · 95% CI 0.63 to 1.29Hazard ratio \<1 favours olaparib.
SecondaryObjective Response Rate (ORR) Using Blinded Independent Central Review (BICR) Data Assessed by Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1)

Number of responders according to blinded independent central review (BICR) assessment. Per Response Evaluation Criteria In Solid Tumours Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR) is defined as the disappearance of all target lesions; Partial Response (PR) is defined as \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response = CR + PR.

Time frame:
Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.
Reported as:
Number · Participants
Objective Response Rate (ORR) Using Blinded Independent Central Review (BICR) Data Assessed by Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1)
ParticipantsOlaparib 300 mg bdChemotherapy
Objective Response Rate (ORR) Using Blinded Independent Central Review (BICR) Data Assessed by Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1)10019
SecondaryAdjusted Mean Change in Global Health Status/Quality of Life (QoL) Score From the European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire (EORTC QLQ-C30)

Change from baseline in global health status/quality of life (QoL) score assessed using a mixed model for repeated measures (MMRM) analysis, including all post-baseline global health status/QoL scores up to the latest scheduled visit where at least 20 patients on each treatment arm have a score. Global health status/QoL score is on a scale from 0 to 100. A higher score represents an improved health status/QoL.

Time frame:
EORTC QLQ-C30 assessments performed at baseline then every ~6 weeks until objective radiological disease progression. Assessed up to a maximum of 30 months.
Reported as:
Mean · Score on a scale
Adjusted Mean Change in Global Health Status/Quality of Life (QoL) Score From the European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire (EORTC QLQ-C30)
Score on a scaleOlaparib 300 mg bdChemotherapy
Adjusted Mean Change in Global Health Status/Quality of Life (QoL) Score From the European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire (EORTC QLQ-C30)3.9 (1.5 to 6.3)-3.6 (-8.0 to 0.8)
Statistical analysis
  • Olaparib 300 mg bd vs Chemotherapy · Mixed Models Analysis · p = 0.0035 · Mean difference (final values): 7.5 · 95% CI 2.5 to 12.4Mean difference \>0 favours olaparib.
SecondaryProgression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) in Patients Confirmed as Myriad CDx gBRCAm

Time from randomisation to the earliest of objective radiological progression or death by any cause in the absence of objective progression. Objective radiological progression is defined using Response Evaluation Criteria In Solid Tumours Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Assessed in patients with a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (gene sequencing and large rearrangement analysis).

Time frame:
Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.
Reported as:
Median · Months
Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) in Patients Confirmed as Myriad CDx gBRCAm
MonthsOlaparib 300 mg bdChemotherapy
Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) in Patients Confirmed as Myriad CDx gBRCAm7.4 (5.7 to 8.3)4.2 (2.8 to 4.3)
Statistical analysis
  • Olaparib 300 mg bd vs Chemotherapy · Log Rank · p = 0.0005 · Hazard ratio (hr): 0.57 · 95% CI 0.41 to 0.78Hazard ratio \<1 favours olaparib.
Other pre-specifiedTime to First Subsequent Cancer Therapy or Death (TFST)

Time from randomisation to the earliest of first subsequent cancer therapy start date following study treatment discontinuation, or death.

Time frame:
Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation. Assessed up to a maximum of 30 months.
Reported as:
Median · Months
Time to First Subsequent Cancer Therapy or Death (TFST)
MonthsOlaparib 300 mg bdChemotherapy
Time to First Subsequent Cancer Therapy or Death (TFST)9.4 (8.3 to 10.6)4.2 (3.3 to 5.2)
Statistical analysis
  • Olaparib 300 mg bd vs Chemotherapy · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.34 · 95% CI 0.24 to 0.47Hazard ratio \<1 favours olaparib.
Other pre-specifiedTime to Second Subsequent Cancer Therapy or Death (TSST)

Time from randomisation to the earliest of second subsequent cancer therapy start date following study treatment discontinuation, or death.

Time frame:
Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation. Assessed up to a maximum of 30 months.
Reported as:
Median · Months
Time to Second Subsequent Cancer Therapy or Death (TSST)
MonthsOlaparib 300 mg bdChemotherapy
Time to Second Subsequent Cancer Therapy or Death (TSST)14.3 (12.2 to 15.5)10.5 (8.4 to 11.3)
Statistical analysis
  • Olaparib 300 mg bd vs Chemotherapy · Log Rank · p = 0.0002 · Hazard ratio (hr): 0.53 · 95% CI 0.38 to 0.74Hazard ratio \<1 favours olaparib.
SecondaryOverall Survival (OS) at Final OS

Time from randomisation until death due to any cause.

Time frame:
Survival status reviewed every 3 weeks until treatment discontinued, then every 8 weeks. Assessed up to a maximum of 40 months.
Reported as:
Median · Months
Overall Survival (OS) at Final OS
MonthsOlaparib 300 mg bdChemotherapy
Overall Survival (OS) at Final OS19.3 (17.2 to 21.6)17.1 (13.9 to 21.9)
Statistical analysis
  • Olaparib 300 mg bd vs Chemotherapy · Log Rank · p = 0.5131 (OS tested using a multiple testing procedure with a recycling strategy. With 192 OS events, a priori threshold for statistical significance was 0.045.) · Hazard ratio (hr): 0.90 · 95% CI 0.66 to 1.23Hazard ratio \<1 favours olaparib.
SecondaryOverall Survival (OS) at Extended OS

Time from randomisation until death due to any cause.

Time frame:
Survival status reviewed every 3 weeks until treatment discontinued, then every 8 weeks until Sep 2017 (final OS DCO), then every 3 months. Assessed up to a maximum of 64 months.
Reported as:
Median · Months
Overall Survival (OS) at Extended OS
MonthsOlaparib 300 mg bdChemotherapy
Overall Survival (OS) at Extended OS19.3 (17.2 to 21.6)17.1 (13.9 to 21.9)
Statistical analysis
  • Olaparib 300 mg bd vs Chemotherapy · Log Rank · p = 0.4167 · Hazard ratio (hr): 0.89 · 95% CI 0.67 to 1.18Hazard ratio \<1 favours olaparib.
Other pre-specifiedTime to First Subsequent Cancer Therapy or Death (TFST) at Extended OS

Time from randomisation to the earliest of first subsequent cancer therapy start date following study treatment discontinuation, or death.

Time frame:
Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation until Sep 2017 (final OS DCO), then every 3 months. Assessed up to a maximum of 64 months.
Reported as:
Median · Months
Time to First Subsequent Cancer Therapy or Death (TFST) at Extended OS
MonthsOlaparib 300 mg bdChemotherapy
Time to First Subsequent Cancer Therapy or Death (TFST) at Extended OS9.4 (8.3 to 10.6)4.3 (3.4 to 5.4)
Statistical analysis
  • Olaparib 300 mg bd vs Chemotherapy · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.36 · 95% CI 0.27 to 0.50Hazard ratio \<1 favours olaparib.
Other pre-specifiedTime to Second Subsequent Cancer Therapy or Death (TSST) at Extended OS

Time from randomisation to the earliest of second subsequent cancer therapy start date following study treatment discontinuation, or death.

Time frame:
Subsequent cancer therapy status reviewed every 8 weeks following study treatment discontinuation until Sep 2017 (final OS DCO), then every 3 months. Assessed up to a maximum of 64 months.
Reported as:
Median · Months
Time to Second Subsequent Cancer Therapy or Death (TSST) at Extended OS
MonthsOlaparib 300 mg bdChemotherapy
Time to Second Subsequent Cancer Therapy or Death (TSST) at Extended OS14.3 (12.3 to 15.7)10.5 (8.5 to 11.3)
Statistical analysis
  • Olaparib 300 mg bd vs Chemotherapy · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.54 · 95% CI 0.40 to 0.72Hazard ratio \<1 favours olaparib.

Adverse events

Collected over Adverse events and serious adverse events were collected throughout the study until study completion (up to a maximum of 30 months). They are reported from date of first dose of study treatment until the earliest of 30 days after last dose of study treatment and data cut-off.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olaparib 300 mg bd159/205 (77.6%)37/205 (18%)196/205 (95.6%)
Chemotherapy73/97 (75.3%)15/91 (16.5%)85/91 (93.4%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventOlaparib 300 mg bdChemotherapy
AnaemiaBlood and lymphatic system disorders5/2052/91
Febrile neutropeniaBlood and lymphatic system disorders0/2052/91
DyspnoeaRespiratory, thoracic and mediastinal disorders4/2050/91
PyrexiaGeneral disorders3/2050/91
Febrile bone marrow aplasiaBlood and lymphatic system disorders0/2051/91
NeutropeniaBlood and lymphatic system disorders0/2051/91
AscitesGastrointestinal disorders0/2051/91
DiarrhoeaGastrointestinal disorders0/2051/91
NauseaGastrointestinal disorders0/2051/91
VomitingGastrointestinal disorders0/2051/91
Most frequent other events
Showing 10 of 45
Most frequent other events
EventOlaparib 300 mg bdChemotherapy
NauseaGastrointestinal disorders119/20531/91
AnaemiaBlood and lymphatic system disorders76/20521/91
VomitingGastrointestinal disorders66/20513/91
FatigueGeneral disorders61/20522/91
NeutropeniaBlood and lymphatic system disorders37/20527/91
DiarrhoeaGastrointestinal disorders42/20519/91
White blood cell count decreasedInvestigations33/20519/91
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders1/20519/91
HeadacheNervous system disorders41/20514/91
Neutrophil count decreasedInvestigations21/20517/91

Baseline characteristics

Full analysis set consisting of all randomized patients.

Age, Continuous
Age, Continuous(Years)Olaparib 300 mg bdChemotherapyTotal
Age (years)44 (22 to 76)45 (24 to 68)44 (22 to 76)
Age, Customized
Age, Customized(Participants)Olaparib 300 mg bdChemotherapyTotal
<5013863201
>=50-<65563086
>=6511415
Sex: Female, Male
Sex: Female, Male(Participants)Olaparib 300 mg bdChemotherapyTotal
Female20095295
Male527
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Olaparib 300 mg bdChemotherapyTotal
American Indian or Alaska Native314
Asian662894
Native Hawaiian or Other Pacific Islander000
Black or African American145
White13463197
More than one race000
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(Participants)Olaparib 300 mg bdChemotherapyTotal
Global — BULGARIA448
Global — CHINA32941
Global — CZECH REPUBLIC11112
Global — FRANCE549
Global — HUNGARY10010
Global — ITALY17724
Global — JAPAN15924
Global — KOREA11920
Global — MEXICO145
Global — PERU314
Global — POLAND10515
Global — ROMANIA112
Global — RUSSIAN FEDERATION10515
Global — SPAIN7613
Global — SWITZERLAND628
Global — TAIWAN112
Global — TURKEY8614
Global — UNITED KINGDOM8412
Global — UNITED STATES451964
Receptor status
Receptor status(Participants)Olaparib 300 mg bdChemotherapyTotal
ER and/or PgR positive10349152
ER and PgR negative10248150
Received prior chemotherapy for metastatic breast cancer
Received prior chemotherapy for metastatic breast cancer(Participants)Olaparib 300 mg bdChemotherapyTotal
Yes14669215
No592887
Received prior platinum for breast cancer
Received prior platinum for breast cancer(Participants)Olaparib 300 mg bdChemotherapyTotal
Yes602686
No14571216
08

Study locations

171 sites
  • Research Site
    San Diego, California 92123, United States
  • Research Site
    Santa Rosa, California 95403, United States
  • Research Site
    Whittier, California 90602, United States
  • Research Site
    Denver, Colorado 80204, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Washington D.C., District of Columbia 20007, United States
  • Research Site
    Jacksonville, Florida 32224, United States
  • Research Site
    Orlando, Florida 32804, United States
  • Research Site
    Plantation, Florida 33324, United States
  • Research Site
    Columbus, Georgia 31904, United States
  • Research Site
    Marietta, Georgia 30060, United States
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Niles, Illinois 60714, United States
  • Research Site
    Wichita, Kansas 67214, United States
  • Research Site
    Lafayette, Louisiana 70506, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Boston, Massachusetts 02118, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Grand Rapids, Michigan 49503, United States
  • Research Site
    Rochester, Minnesota 55905-0001, United States
  • Research Site
    Saint Louis Park, Minnesota 55416, United States
  • Research Site
    Jackson, Mississippi 39202, United States
  • Research Site
    Columbia, Missouri 65212, United States
  • Research Site
    St Louis, Missouri 63131, United States
  • Research Site
    Lebanon, New Hampshire 03756, United States
  • Research Site
    Commack, New York 11725, United States
  • Research Site
    Harrison, New York 10604, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Rockville Centre, New York 11570, United States
  • Research Site
    Syracuse, New York 13210, United States
  • Research Site
    Cincinnati, Ohio 45267, United States
  • Research Site
    Cleveland, Ohio 44106, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Portland, Oregon 97213, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Sayre, Pennsylvania 18840, United States
  • Research Site
    Germantown, Tennessee 38138, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Tyler, Texas 75701, United States
  • Research Site
    Burlington, Vermont 05401, United States
  • Research Site
    Plovdiv, 4000, Bulgaria
  • Research Site
    Plovdiv, 4004, Bulgaria
  • Research Site
    Sofia, 1233, Bulgaria
  • Research Site
    Sofia, 1303, Bulgaria
  • Research Site
    Sofia, 1330, Bulgaria
  • Research Site
    Sofia, 1504, Bulgaria
  • Research Site
    Varna, 9010, Bulgaria
  • Research Site
    Vratsa, 3000, Bulgaria
  • Research Site
    Beijing, 100006, China
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Changchun, 130061, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Dalian, 116011, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Shanghai, 200025, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenyang, 110016, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Brno, 656 53, Czechia
  • Research Site
    Olomouc, 775 20, Czechia
  • Research Site
    Prague, 128 08, Czechia
  • Research Site
    Caen, 14076, France
  • Research Site
    Montpellier, 34298, France
  • Research Site
    Rouen, 76038, France
  • Research Site
    Strasbourg, 67065, France
  • Research Site
    Villejuif, 94800, France
  • Research Site
    Budapest, 1032, Hungary
  • Research Site
    Budapest, 1083, Hungary
  • Research Site
    Budapest, 1115, Hungary
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Budapest, 1145, Hungary
  • Research Site
    Nyíregyháza, 4400, Hungary
  • Research Site
    Veszprém, 8200, Hungary
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Roma, 00144, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Rozzano, 20089, Italy
  • Research Site
    Chūōku, 104-0045, Japan
  • Research Site
    Chūōku, 104-8560, Japan
  • Research Site
    Fukuoka, 811-1395, Japan
  • Research Site
    Kagoshima, 892-0833, Japan
  • Research Site
    Nagoya, 464-8681, Japan
  • Research Site
    Osaka, 540-0006, Japan
  • Research Site
    Sapporo, 003-0804, Japan
  • Research Site
    Shinagawa-ku, 142-8666, Japan
  • Research Site
    Suita, 565-0871, Japan
  • Research Site
    Estado de México, 50080, Mexico
  • Research Site
    Mérida, 97000, Mexico
  • Research Site
    Mérida, 97070, Mexico
  • Research Site
    Mérida, 97133, Mexico
  • Research Site
    México, 6760, Mexico

Showing the first 100 of 171 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. doi: 10.1056/NEJMoa1706450. Epub 2017 Jun 4. PubMed 28578601 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Dec 2016, 32 months.

Results were first posted in Dec 2017, 1 year after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 32 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2013
First posted
Dec 4, 2013
StartActual
Mar 27, 2014
Primary completionActual
Dec 9, 2016
CompletionActual
Dec 23, 2025
Results first posted
Dec 22, 2017
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02000622
Lead sponsor
AstraZeneca
Collaborators
Myriad Genetic Laboratories, Inc., Merck Sharp & Dohme LLC
Responsible party
Sponsor
First posted
Dec 4, 2013
Start date
Mar 27, 2014
Primary completion
Dec 9, 2016
Completion
Dec 23, 2025
Results posted
Dec 22, 2017
Last update
Feb 13, 2026

Study contacts

Mark Robson, MD
principal investigator · Memorial Sloan-Kettering Cancer Center, New York

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion